ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer advances stand-alone torcetrapib

July 31, 2006 | APPEARED IN VOLUME 84, ISSUE 31

Pfizer intends to file an Investigational New Drug Application for torcetrapib, a heart treatment that raises levels of so-called "good cholesterol," as a stand-alone drug. The firm has been developing torcetrapib exclusively in combination with its market-leading cholesterol drug Lipitor, which is due to come off patent in 2011. Although Pfizer claims the combination therapy has the potential to revolutionize the treatment of cardiovascular disease, cardiologists and others contend there is no medical reason to combine the drugs. Pfizer says it is considering all options for torcetrapib.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment